Innate Pharma (IPHA)

Earnings in 2023: -HK$65.1 Million

According to Innate Pharma 's latest financial reports the company's current earnings are HK$57.37 Million. In 2023 the company made an earning of -HK$65.1 Million, an increase over its 2022 earnings that were of -HK$0.49 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Innate Pharma from 2005 to 2023

Annual earnings

Year	Earnings	Change
2023	-HK$65.1 Million	-86.54%
2022	-HK$0.49 Billion	20.74%
2021	-HK$0.41 Billion	4951.09%
2020	-HK$7.94 Million	-111.57%
2019	HK$68.55 M	183.46%
2018	HK$24.18 M	-105.4%
2017	-HK$0.45 Billion	-523.25%
2016	HK$0.10 B	-285.64%
2015	-HK$57.04 Million	-69.31%
2014	-HK$0.19 Billion	498.29%
2013	-HK$31.07 Million	-5.62%
2012	-HK$32.92 Million	-53.32%
2011	-HK$70.51 Million	-50.1%
2010	-HK$0.15 Billion	-13.3%
2009	-HK$0.17 Billion	26.36%
2008	-HK$0.13 Billion	27.35%
2007	-HK$0.11 Billion	63.33%
2006	-HK$62.02 Million	9.81%
2005	-HK$56.48 Million

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Earnings for Innate Pharma (IPHA)